Charles R. Kerr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Charles R. Kerr has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Stuart J. Connolly
Hamilton General Hospital, Hamilton, Ontario, Canada
4 shared publicationsGeorge J. Klein
University of Western Ontario, London, Ontario, Canada
3 shared publications- Mario Talajic
Montreal Heart Institute, University of Montreal, Montreal, Canada
3 shared publications Karin H. Humphries
Centre for Health Evaluation and Outcomes Sciences, Vancouver, British Columbia, Canada
2 shared publicationsMartin Green
Ottawa Heart Institute, Ottawa, Ontario, Canada
2 shared publicationsPaul Dorian
St. Michael's Hospital and the University of Toronto, Toronto, Ontario, Canada
2 shared publications
Latest Publications
- 1 September 2010
- Published by Elsevier in Heart Rhythm
- Vol. 7 (9) , 1171-1177
Antiarrhythmic use from 1991 to 2007: Insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II)
- 1 September 2010
- Published by Elsevier in Heart Rhythm
- Vol. 7 (9) , 1171-1177
Antiarrhythmic use from 1991 to 2007: Insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II)
- 1 March 2005
- Published by Elsevier in American Heart Journal
- Vol. 149 (3) , 489-496
Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation
- 1 March 2005
- Published by Elsevier in American Heart Journal
- Vol. 149 (3) , 489-496
Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation
- 27 January 2004
- Published by Wolters Kluwer Health in Circulation
- Vol. 109 (3) , 357-362
Canadian Trial of Physiological Pacing
Background— The Canadian Trial of Physiological Pacing (CTOPP) reported that the risk of stroke or cardiovascular death was similar between patients receiving ventricular versus physiological pacemakers at the end of the original follow-up period of 3 years. However, the occurrence of atrial fibrillation was significantly less frequent with physiological pacemakers. To assess a potential delayed benefit of physiological pacing, follow-up of patients in this study was extended to 6 years. Methods and Results— A total of 1474 patients requiring a pacemaker for symptomatic bradycardia were randomized to receive ventricular and 1094 to physiological pacemakers. The primary outcome was stroke or cardiovascular death. The study was completed in July 1998, and follow-up was extended to July 2001. At a mean follow-up of 6.4 years, there was no difference between treatment groups in the primary outcome of cardiovascular death or stroke. There was no significant difference in total mortality or stroke between groups. There was a significantly lower rate of development of atrial fibrillation in the physiological group, with a relative risk reduction of 20.1% (CI, 5.4 to 32.5; P =0.009). Conclusions— The CTOPP extended study does not show a difference in cardiovascular death or stroke, or in total mortality, or in stroke between patients implanted with ventricular or physiological pacemakers over a mean follow-up of >6 years. However, there is a persistent significant reduction in the development of atrial fibrillation with physiological pacing.
- 27 January 2004
- Published by Wolters Kluwer Health in Circulation
- Vol. 109 (3) , 357-362
Canadian Trial of Physiological Pacing
Background— The Canadian Trial of Physiological Pacing (CTOPP) reported that the risk of stroke or cardiovascular death was similar between patients receiving ventricular versus physiological pacemakers at the end of the original follow-up period of 3 years. However, the occurrence of atrial fibrillation was significantly less frequent with physiological pacemakers. To assess a potential delayed benefit of physiological pacing, follow-up of patients in this study was extended to 6 years. Methods and Results— A total of 1474 patients requiring a pacemaker for symptomatic bradycardia were randomized to receive ventricular and 1094 to physiological pacemakers. The primary outcome was stroke or cardiovascular death. The study was completed in July 1998, and follow-up was extended to July 2001. At a mean follow-up of 6.4 years, there was no difference between treatment groups in the primary outcome of cardiovascular death or stroke. There was no significant difference in total mortality or stroke between groups. There was a significantly lower rate of development of atrial fibrillation in the physiological group, with a relative risk reduction of 20.1% (CI, 5.4 to 32.5; P =0.009). Conclusions— The CTOPP extended study does not show a difference in cardiovascular death or stroke, or in total mortality, or in stroke between patients implanted with ventricular or physiological pacemakers over a mean follow-up of >6 years. However, there is a persistent significant reduction in the development of atrial fibrillation with physiological pacing.
- 1 January 2003
- Vol. 19 (1) , 21-37
Guidelines for implantable cardioverter defibrillator follow-up in Canada: a consensus statement of the Canadian Working Group on Cardiac Pacing.
A survey on the follow-up practices of patients with implantable cardioverter defibrillators (ICDs) in Canada was conducted by the Canadian Working Group on Cardiac Pacing in 1999. The survey identified the need for national guidelines. The present guidelines for ICD follow-up represent a consensus statement of the Canadian Working Group on Cardiac Pacing. They recommend that patients be assessed before hospital discharge, at two to 12 weeks following implantation, six months after implantation, and at a minimum of every six months thereafter. More frequent assessments may be required for some patients depending on associated cardiovascular problems and specific ICD devices. A typical follow-up visit should include a targeted cardiovascular assessment, interrogation of the ICD, review of telemetered data, assessment of the underlying rhythm, pacing and sensing thresholds, lead impedance and appropriate reprogramming of ICD parameters to optimize device function and longevity.
- 1 January 2003
- Vol. 19 (1) , 21-37
Guidelines for implantable cardioverter defibrillator follow-up in Canada: a consensus statement of the Canadian Working Group on Cardiac Pacing.
A survey on the follow-up practices of patients with implantable cardioverter defibrillators (ICDs) in Canada was conducted by the Canadian Working Group on Cardiac Pacing in 1999. The survey identified the need for national guidelines. The present guidelines for ICD follow-up represent a consensus statement of the Canadian Working Group on Cardiac Pacing. They recommend that patients be assessed before hospital discharge, at two to 12 weeks following implantation, six months after implantation, and at a minimum of every six months thereafter. More frequent assessments may be required for some patients depending on associated cardiovascular problems and specific ICD devices. A typical follow-up visit should include a targeted cardiovascular assessment, interrogation of the ICD, review of telemetered data, assessment of the underlying rhythm, pacing and sensing thresholds, lead impedance and appropriate reprogramming of ICD parameters to optimize device function and longevity.